Nasdaq:US$13.35 (+0.09) | HKEX:HK$20.80 (+0.08) | AIM:£2.01 (-0.03)
搜索
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2007-11-22

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients